Biofrontera Inc. (BFRI) · Nov 20, 2026 · Delisting

Biofrontera Nasdaq warning returns as cash pressure clouds Ameluz launch

Bid-price deficiency — Below $1.00 for 30 business days; cure deadline May 17, 2027

Biofrontera’s Nasdaq minimum-bid warning is back, giving the company until May 2027 to avoid a deeper listing problem while cash remains tight.

Biofrontera is commercializing Ameluz and its photodynamic-therapy lamps in the U.S., while trying to launch Ameluz for superficial basal cell carcinoma after its September 2026 FDA approval. The business is growing revenue, but the latest quarterly filing showed only $3.2 million of cash, continued operating cash burn, and substantial doubt about funding operations without additional financing or other liquidity measures.

The filing adds another listing problem, not an immediate trading halt. Nasdaq says Biofrontera’s closing bid price stayed below $1.00 for 30 consecutive business days, triggering a deficiency under Rule 5550(a)(2). The notice does not currently affect listing or trading, and the company has until May 17, 2027 to record a closing bid of at least $1.00 for 10 consecutive business days. 〔0〕

This is a manageable deadline, but it reinforces a broader financing vulnerability. The notice itself was foreseeable: Biofrontera’s November 13 quarterly filing said it expected a Nasdaq deficiency notice after reporting, so the event is partly known rather than a surprise. But the company is now again facing a minimum-price cure period alongside a separate stockholders’ equity listing issue and a stated need for outside funding, making a reverse split or other capital-market action a live contingency rather than a distant possibility.

A reverse split is a backstop, not a business fix. If Biofrontera cannot restore the bid price, Nasdaq may grant additional time if other listing standards are met, but the filing explicitly identifies a reverse stock split as a possible cure and warns that delisting remains possible. 〔1〕

Bottom line: This does not change Biofrontera’s operations today, but it adds another deadline to an already cash-constrained commercialization story. The issue is modestly negative because the risk was anticipated, yet the company still has to solve it while funding the Ameluz expansion and avoiding further listing deficiencies.

What to watch next

Ameluz sBCC commercialization, late Q4 2026 to Q1 2027

Original filing on SEC EDGAR

Biofrontera Nasdaq warning returns as cash pressure clouds Ameluz launch | BFRI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.